马来酸依那普利与瑞舒伐他汀对高血压合并心房颤动上游防治的临床效果

Clinical efficacy of enalapril maleate and rosuvastatin on prevention and treatment of hypertension complicated with upstream of atrial fibrillation

目的:探讨马来酸依那普利与瑞舒伐他汀对高血压合并心房颤动上游防治的临床效果。方法:选择144例高血压合并阵发性心房颤动患者,随机分为马来酸依那普利组(35例)、马来酸依那普利+瑞舒伐他汀组(36例)、瑞舒伐他汀+苯磺酸左旋氨氯地平组(36例)、苯磺酸左旋氨氯地平组(37例),比较四组临床效果。结果:马来酸依那普利+瑞舒伐他汀组阵发性房颤转化为持续性房颤的发生率(8. 33%)低于马来酸依那普利组(25. 71%)、瑞舒伐他汀+苯磺酸左旋氨氯地平组(22. 22%)、苯磺酸左旋氨氯地平组(27. 03%)(P <0. 05),马来酸依那普利+瑞舒伐他汀组心功能减退至Ⅲ级、Ⅳ级占19. 44%,低于马来酸依那普利组(34. 29%)、瑞舒伐他汀+苯磺酸左旋氨氯地平组(30. 56%)、苯磺酸左旋氨氯地平组(32. 43%)(P <0. 05)。结论:马来酸依那普利与瑞舒伐他汀联合治疗高血压合并心房颤动可起到较好的二级预防效果。

Objective:To explore the clinical efficacy of enalapril maleate and rosuvastatin on prevention and treatment of hypertension complicated with paroxysmal atrial fibrillation.Methods:144patients with hypertension complicated with paroxysmal atrial fibrillation were chosen and divided into Group Enalapril maleate(35cases),Group Enalapril maleate+rosuvastatin(36cases),Group Rosuvastatin+levamlodipine besylate(36cases),and Group levamlodipine besylate(37cases),with the clinical efficacy of the four groups compared.Results:The incidence of paroxysmal atrial fibrillation into persistent atrial fibrillation in Group Enalapril maleate+rosuvastatin(8.33%)was significantly lower than those in Group Enalapril maleate(25.71%),Group Rosuvastatin+levamlodipine besylate(22.22%)and Group Levamlodipine besylate(27.03%)(P<0.05).The cardiac function of Group Enalapril maleate+rosuvastatin decreased to Grade III and Grade IV(19.44%),lower than those of Group Enalapril maleate(34.29%),Group Rosuvastatin+levamlodipine besylate(30.56%),and Group Levamlodipine besylate(32.43%)(P<0.05).Conclusion:Combination of enalapril maleate and rosuvastatin in the treatment of patients with hypertension and atrial fibrillation can have a better secondary prevention effect.